Results - location/WA/6008-Subiaco-Bendat-Family-Comprehensive-Cancer-Centre-St-John-of-God-Subiaco-Hospital - ARTICANZ

ARTICANZ - Beta (ver 0.91)

Annotated Registry of Trials in Cancer, Australia and New Zealand Ed. - Results - location/WA/6008-Subiaco-Bendat-Family-Comprehensive-Cancer-Centre-St-John-of-God-Subiaco-Hospital

Search results

22 trial(s) found.

Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations (1479-0032)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer (FLORENZA)

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01) (D6900C00003)

A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma (PEAK-1)

IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment (CA244-0008)

A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer (BNT324-01)

A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05) (DS8201-724)

A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors (CA244-0001)

Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (1479-0009)

A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment (JZP598-303)

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) (DS7300-203)

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

3844 - Traralgon - Latrobe Regional Hospital (WITHDRAWN)

SA5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (WITHDRAWN)

An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (ProvIDHe)

NSW2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (COMPLETED)

VIC3065 - Fitzroy - St Vincent's Hospital Melbourne (COMPLETED)

QLD4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (COMPLETED)

SA5011 - Woodville South - The Queen Elizabeth Hospital (COMPLETED)

WA6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (COMPLETED)

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements (FOENIX-CCA4)

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (KAT6)

NSW2050 - Camperdown - Chris O'Brien Lifehouse (TERMINATED)

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (3475-587)

2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (COMPLETED)

4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)4120 - Greenslopes - Greenslopes Private Hospital (COMPLETED)

ACTRN12624001120561

Not Applicable

Patient Initiated Follow Up (PIFU) in Endometrial Cancer (PECAN) – a Randomised Pilot Feasibility Study

ACTRN12623000223639

A Phase 1 single-blind study evaluating LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel as a first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC) (iLSTA)

A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND)

Filters

Recruitment Status

Recruitment Country and State

Phase

Trial Type

Cancer Therapy Class

PD-1/PD-L1	27%
ERBB2	18%
PD-1	18%
PD-L1	18%
CDK4	14%
CDK6	14%
ER	14%
oestrogen axis	14%
B7H3	14%
VEGF	9%
EGFR	9%
ERBB3	9%
VEGFA	9%
PI3Kalpha	5%
FR-alpha	5%
B7H4	5%
AXL	5%
HIF2a	5%
KIT	5%
MET	5%
RET	5%
ROS1	5%
VEGFR	5%
VEGFR2	5%
IDH1	5%
IDH1 R132	5%
FGFR	5%
FGFR1	5%
FGFR1/2/3	5%
FGFR2	5%
FGFR3	5%
FGFR4	5%
WEE1	5%
CDK4 selective	5%
KAT6	5%
KAT6A	5%
ER	5%
LAG3	5%
PARP	5%

Facility

Cancer Type

ARTICANZ (Annotated Registry of Trials in Cancer, Australia/NZ Edition; ARTificial Intelligence-enhanced CANcer trial information database) provides information about cancer drug trials in Australia and New Zealand as a free, open-information platform. Please note the following:

Data Accuracy: While ARTICANZ strives to maintain accurate and up-to-date information through regular weekly updates and specialist review, we cannot guarantee the complete accuracy, reliability, or timeliness of all data. Information may change between updates.
Not Medical Advice: The information provided by ARTICANZ is for informational purposes only and should not be considered medical advice. All clinical decisions should be made in consultation with qualified healthcare professionals.
No Warranty: ARTICANZ is provided "as is" without any warranties, expressed or implied. We disclaim all liability for any damages arising from the use of or inability to use this platform.
External Links: ARTICANZ may contain links to external websites. We are not responsible for the content or privacy practices of these sites.

By using ARTICANZ, you acknowledge that you have read and understood this disclaimer.

The ARTICANZ platform and its contents are made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

Users are free to:

Share — copy and redistribute the data in any medium or format
Adapt — remix, transform, and build upon the data
Use the data for any purpose, including commercial use

Under the following terms:

Attribution — You must give appropriate credit to ARTICANZ, provide a link to the license, and indicate if changes were made
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits

Platform developed and currently maintained by Dr. Frank Lin and the ARTICANZ team.